" class="no-js "lang="en-US"> Renalis - Medtech Alert
Sunday, October 19, 2025

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
Renalis | Pharmtech Focus

Renalis

About Renalis

Renalis

Renalis is creating a suite of prescribed digital therapeutics (PDT) designed for patients with pelvic health disorders such as overactive bladder (OAB), fecal incontinence, fibroids, endometriosis or chronic pelvic pain. The company’s first go-to-market platform for fibroids/endo will be available 3Q20, followed by another for OAB, for which the company anticipates seeking FDA approval in 2021 following clinical trials. Renalis is based in Chicago at MATTER, but serves a global market.

Related Story

Fundraising

 Healthcare Startup

Healthcare Startup, Renalis, Raises $824K to Accelerate its Digital Health Platform

September 1 2021

Renalis, a Cleveland-based digital health company committed to the treatment of pelvic health disorders, announced the […]